The FDA is approving the first new Alzheimer's drug in nearly two decades. However, it’s not without controversy. Massachusetts-based Biogen makes the drug called Aducanumab. It's injectable and is supposed to slow cognitive decline in early-stage dementia patients.
"A lot of families are willing to bank on this drug so their loved ones will have a better and longer life," said ABC News Correspondent Jim Ryan while on the "Len Berman and Michael Riedel In The Morning" show.
To hear the full convo with Jim Ryan check out the podcast below...